4.6 Article

Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2

Journal

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 84, Issue 11, Pages 1247-1249

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2013-305049

Keywords

-

Funding

  1. National Institutes of Neurological Diseases and Stroke [5R01NS054132, 5R01NS052767, U54NS065712, NS060983]
  2. National Institute of General Medical Science [1R01GM088278]
  3. Rackham Merit Fellowship
  4. National Institutes of Health Genetics Training Grant [T32 GM007544-32]
  5. Medical Research Council (MRC)
  6. Wellcome Trust
  7. Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme
  8. Medical Research Council [MR/K000608/1, G108/638, MR/J004758/1, G1001253, G0802760] Funding Source: researchfish
  9. MRC [MR/J004758/1, G0802760, MR/K000608/1, G1001253, G108/638] Funding Source: UKRI

Ask authors/readers for more resources

Charcot-Marie-Tooth (CMT) disease is a genetically heterogeneous condition with >50 genes now being identified. Thanks to new technological developments, namely, exome sequencing, the ability to identify additional rare genes in CMT has been drastically improved. Here we present data suggesting that MARS is a very rare novel cause of late-onset CMT2. This is supported by strong functional and evolutionary evidence, yet the absence of additional unrelated cases warrant future studies to substantiate this conclusion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available